A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)

被引：30
|
作者：
De Jesus-Acosta, Ana
O'Dwyer, Peter J.
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Maitra, Anirban
Rasheed, Zeshaan
Zheng, Lei
Rajeshkumar, N. V.
Le, Dung T.
Hoering, Antje
Bolejack, Vanessa
Yabuuchi, Shinichi
Laheru, Daniel A.
机构：
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Scottsdale HealthCare, Scottsdale, AZ USA
[4] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Canc Res & Biostat, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.257
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
257
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer
    Davis, S. Lindsey
    Cardin, Dana Backlund
    Shahda, Safi
    Lenz, Heinz-Josef
    Dotan, Efrat
    O'Neil, Bert
    Kapoun, Ann M.
    Stagg, Robert J.
    Berlin, Jordan
    Messersmith, Wells A.
    Cohen, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [42] LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).
    Philip, Philip Agop
    Lacy, Jill
    Dowden, Scot D.
    Sastre, Javier
    Bathini, Venu Gopal
    Cardin, Dana Backlund
    Ma, Wen Wee
    Sobrero, Alberto F.
    Koski, Sheryl L.
    Borg, Christophe
    Tonini, Giuseppe
    Rivera, Fernando
    Hwang, Jimmy J.
    Knoble, Jeanna L.
    Al Baghdadi, Tareq
    Saif, Wasif M.
    Meiri, Eyal
    Kayitalire, Louis
    Li, Jack
    Hammel, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [43] Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis
    Takashi Kaneko
    Kazuya Sugimori
    Yuichiro Tozuka
    Taito Fukushima
    Kazuya Okada
    Hiroyuki Oka
    Hiroshi Okazaki
    Shin Maeda
    Clinical Journal of Gastroenterology, 2019, 12 : 484 - 489
  • [44] APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma
    Pignon, Flore
    Turpin, Anthony
    Hentic, Olivia
    Coriat, Romain
    Salmon, Emma
    Baumgaertner, Isabelle
    Bertrand, Nicolas
    Levy, Philippe
    Rebours, Vinciane
    Hammel, Pascal
    de Mestier, Louis
    PANCREATOLOGY, 2021, 21 (06) : 1064 - 1070
  • [46] Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, W.
    Kornek, G.
    Prager, G.
    Stranzl, N.
    Laengle, F.
    Schindl, M.
    Friedl, J.
    Klech, J.
    Roethlin, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [47] Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress)
    Bajor, David Lawrence
    Gutierrez, Martin
    Vaccaro, Gina M.
    Masood, Ashiq
    Brown-Glaberman, Ursa Abigail
    Grilley-Olson, Juneko E.
    Javle, Milind M.
    Kindler, Hedy L.
    Gbolahan, Olumide B.
    Shields, Anthony Frank
    Zalupski, Mark
    Schmitt, Michael W.
    Coveler, Andrew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).
    Goldstein, David
    Von Hoff, Daniel D.
    Chiorean, E. Gabriela
    Reni, Michele
    Tabernero, Josep
    Ramanathan, Ramesh K.
    Aly, Abdalla
    Botteman, Marc
    Wilkersen, Julia
    Margunato-Debay, Sandra
    Lu, Brian
    Louis, Chrystal Ursula
    Renschler, Markus Frederic
    McGovern, Desmond Micahel Thomas
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis
    Kaneko, Takashi
    Sugimori, Kazuya
    Tozuka, Yuichiro
    Fukushima, Taito
    Okada, Kazuya
    Oka, Hiroyuki
    Okazaki, Hiroshi
    Maeda, Shin
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2019, 12 (05) : 484 - 489
  • [50] Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, Werner
    Kornek, Gabriela
    Prager, Gerald
    Stranzl, Nadja
    Laengle, Friedrich
    Schindl, Martin
    Friedl, Josef
    Klech, Julia
    Roethlin, Sabine
    Zielinski, Christoph
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (02) : 234 - 238
12345